Cargando…

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide

Detalles Bibliográficos
Autores principales: Astrup, A, Carraro, R, Finer, N, Harper, A, Kunesova, M, Lean, M E J, Niskanen, L, Rasmussen, M F, Rissanen, A, Rössner, S, Savolainen, M J, Van Gaal, L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461573/
http://dx.doi.org/10.1038/ijo.2011.203
_version_ 1782245095414693888
author Astrup, A
Carraro, R
Finer, N
Harper, A
Kunesova, M
Lean, M E J
Niskanen, L
Rasmussen, M F
Rissanen, A
Rössner, S
Savolainen, M J
Van Gaal, L
author_facet Astrup, A
Carraro, R
Finer, N
Harper, A
Kunesova, M
Lean, M E J
Niskanen, L
Rasmussen, M F
Rissanen, A
Rössner, S
Savolainen, M J
Van Gaal, L
author_sort Astrup, A
collection PubMed
description
format Online
Article
Text
id pubmed-3461573
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-34615732012-10-03 Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide Astrup, A Carraro, R Finer, N Harper, A Kunesova, M Lean, M E J Niskanen, L Rasmussen, M F Rissanen, A Rössner, S Savolainen, M J Van Gaal, L Int J Obes (Lond) Corrigendum Nature Publishing Group 2012-06 2012-06-12 /pmc/articles/PMC3461573/ http://dx.doi.org/10.1038/ijo.2011.203 Text en Copyright © 2012 Macmillan Publishers Limited
spellingShingle Corrigendum
Astrup, A
Carraro, R
Finer, N
Harper, A
Kunesova, M
Lean, M E J
Niskanen, L
Rasmussen, M F
Rissanen, A
Rössner, S
Savolainen, M J
Van Gaal, L
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide
title Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide
title_full Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide
title_fullStr Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide
title_full_unstemmed Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide
title_short Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide
title_sort safety, tolerability and sustained weight loss over 2 years with the once-daily human glp-1 analogue, liraglutide
topic Corrigendum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461573/
http://dx.doi.org/10.1038/ijo.2011.203
work_keys_str_mv AT astrupa safetytolerabilityandsustainedweightlossover2yearswiththeoncedailyhumanglp1analogueliraglutide
AT carraror safetytolerabilityandsustainedweightlossover2yearswiththeoncedailyhumanglp1analogueliraglutide
AT finern safetytolerabilityandsustainedweightlossover2yearswiththeoncedailyhumanglp1analogueliraglutide
AT harpera safetytolerabilityandsustainedweightlossover2yearswiththeoncedailyhumanglp1analogueliraglutide
AT kunesovam safetytolerabilityandsustainedweightlossover2yearswiththeoncedailyhumanglp1analogueliraglutide
AT leanmej safetytolerabilityandsustainedweightlossover2yearswiththeoncedailyhumanglp1analogueliraglutide
AT niskanenl safetytolerabilityandsustainedweightlossover2yearswiththeoncedailyhumanglp1analogueliraglutide
AT rasmussenmf safetytolerabilityandsustainedweightlossover2yearswiththeoncedailyhumanglp1analogueliraglutide
AT rissanena safetytolerabilityandsustainedweightlossover2yearswiththeoncedailyhumanglp1analogueliraglutide
AT rossners safetytolerabilityandsustainedweightlossover2yearswiththeoncedailyhumanglp1analogueliraglutide
AT savolainenmj safetytolerabilityandsustainedweightlossover2yearswiththeoncedailyhumanglp1analogueliraglutide
AT vangaall safetytolerabilityandsustainedweightlossover2yearswiththeoncedailyhumanglp1analogueliraglutide